BOONE CAPITAL MANAGEMENT LLC
Long book
$326.4M
Q1 2026
Positions
13
Top-10 weight
91%
concentration
Last quarter
+16.4%
SPY +14.8%
Turnover
60%
of book per quarter
Strategy in plain words
auto-generated from filingsBOONE CAPITAL MANAGEMENT LLC is a concentrated fundamental stock-picker, specialised in healthcare (82% of the long book), running a $326.4M US long book across 13 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: MIRUM PHARMACEUTICALS INC, IONIS PHARMACEUTICALS INC, THE CIGNA GROUP, MEDTRONIC PLC, TELEFLEX INC.
Over the last 9 quarters its long book ran on average 1.3pp per quarter behind the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-12.2%
Q2 2024
+11.8%
Q3 2024
-5.2%
Q4 2024
-0.6%
Q1 2025
-4.3%
Q2 2025
+7.7%
Q3 2025
+15.5%
Q4 2025
-0.0%
Q1 2026
+16.4%
Sector allocation
Healthcare 82%
Financials 18%
Long book by quarter
What does BOONE CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 421.2K | $38.9M | 11.9% | Held |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 500.5K | $37.6M | 11.5% | +19.8% |
| CI THE CIGNA GROUP | Financials | 137.5K | $36.7M | 11.2% | +42.6% |
| MDT MEDTRONIC PLC | Healthcare | 398.1K | $34.5M | 10.6% | -7.2% |
| TFX TELEFLEX INC | Healthcare | 278.8K | $33.3M | 10.2% | New |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 547.9K | $30.9M | 9.5% | +33.0% |
| GRDN GUARDIAN PHRMCY SERVICES-A | Healthcare | 631.2K | $23.8M | 7.3% | New |
| AZN ASTRAZENECA PLC | Healthcare | 110.1K | $21.7M | 6.7% | New |
| UNH UNITEDHEALTH GROUP INC | Financials | 79.2K | $21.4M | 6.6% | +28.3% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 228.8K | $17.0M | 5.2% | +23.7% |
| AVNS AVANOS MEDICAL INC | Healthcare | 1.2M | $16.6M | 5.1% | New |
| KOD KODIAK SCIENCES INC | Healthcare | 281.3K | $10.7M | 3.3% | -44.2% |
| TENX TENAX THERAPEUTICS INC | Healthcare | 200.0K | $3.2M | 1.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 13 | $326.4M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 15 | $318.6M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 16 | $305.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 11 | $233.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 12 | $293.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 13 | $296.5M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 17 | $385.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 19 | $383.4M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 21 | $494.4M | canonical | SEC ↗ |